Skip to main content

Table 1 The potency and selectivity of all tested monoamine transporter inhibitors

From: Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

  

IC50 (nM) of uptake inhibition

Selectivity factor

Platelets

SK-N-SH

IC50 ratio

[3H]Serotonin

[125I]MIBG

[125I]MIBG

SSRIs

Alaproclate

516

38

43420

1158

Citalopram

32

7.8

11940

1521

Fluvoxamine

30

9.3

2339

252

Fluoxetine

115

32

1270

40

Norfluoxetine

107

24

2760

115

Paroxetine

0.6

0.2

10

45

Sertraline

41

36

3301

91

TCAs

Clomipramine

18

7

176

24

Imipramine

118

104

82

0.8

Desipramine

648

744

5

0.007

TeCA

Maprotiline

n.d.

1000–10,000

39

0.04–0.004

  1. Selective inhibition of 10−8 M [125I]MIBG or [3H]serotonin uptake by monoamine transporter inhibitors in human platelets or SK-N-SH neuroblastoma cells in vitro. Selectivity was expressed as the IC50 ratio of the MIBG uptake in SK-N-SH cells over that in platelets. SSRI Selective serotonin reuptake inhibitor; TCA Tricyclic antidepressant; TeCA Tetracyclic antidepressantÂ